Company intelligence / Profile preview
Cellenkos, Inc.
Houston, Texas, United Statescellenkosinc.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Promising Phase 1b results for CK0804 in myelofibrosis; CK0801 has shown efficacy in aplastic anemia including transfusion independence; FDA Orphan Drug Designation granted to CK0801 for treatment of Aplastic Anemia in April 2025
- Therapeutic areas
- GastroenterologyPulmonologyPsychiatryImmunologyEndocrinologyHematologyNeurology
- Modalities
- T regulatory (Treg) cell therapiesAllogeneic cell therapiesCord blood-derived cell therapies
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
MD Anderson Cancer Center
Beyond the preview
Go deeper on Cellenkos, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cellenkos, Inc..